COL1A2 and Hepatic fibrosis: ATGLi mice displayed lower total NAFLD score (−84%) (Fig. 5i), reduced plasma alanine aminotransferase (ALT) activity (−50%) and decreased mRNA expression levels for both inflammatory markers (Tnfα −62%, F4/80 −55%, Cd11c −71% and Il1β −65%) and markers for hepatic fibrosis (Col1a1 −90%, Col1a2 −80% and Tgfβ −54%) (Fig. 5j,k).